Quantcast

New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years

February 23, 2009

DÃÅ“SSELDORF, Germany, February 23 /PRNewswire/ — An international team of
researchers has evaluated the effectiveness of Orthokine therapy for
osteoarthritis of the knee, and the results have been published in the
February edition of the specialist journal “Osteoarthritis and Cartilage”.
The researchers followed 376 patients to determine the effectiveness of
various osteoarthritis treatments. After six months as well as after two
years, patients who received Orthokine therapy experienced significantly less
pain and more improved joint function than those who received hyaluronic acid
or a placebo. Orthokine therapy is a biotechnology-based method in which
proteins that inhibit inflammation are obtained from the patient’s own blood
and injected into the affected joint.

“In this study and for several thousand patients whom we have treated,
Orthokine has proven an extraordinarily safe and effective way of treating
osteoarthritis of the knee. I am delighted that distinguished experts have
now confirmed these findings,” said Dr. Peter Wehling, CEO of ORTHOGEN AG, in
Düsseldorf on February 21. “We are now planning to distribute the
IP-protected Orthokine technology world- wide. Orthokine is already being
distributed in various EU countries through ORTHOGEN or other distributors.”

Orthokine is the first scientifically proven, placebo-controlled
autologous therapy in the orthopaedic field.

This kind of therapy was recently discussed in The New York Times. Two of
the Pittsburgh Steelers’ biggest stars, Hines Ward and Troy Polamalu, used
their own blood cells in an innovative injury treatment before winning the
Super Bowl.

    To find out more:

http://www.oarsijournal.com/

http://www.oarsi.org

    For more information please contact:
    Orthogen AG
    Press and Public Relations
    Elena Kawadopulos
    Graf-Adolf-Str. 43
    40210 Düsseldorf
    Tel.: +49-211-3670076
    Fax: +49-211-3670010
    Mobile: +49-177-588-3442
    E-Mail: elena.kawadopulos@orthogen.com

http://www.orthogen.com

SOURCE Orthogen AG


Source: newswire



comments powered by Disqus